Table 9Cost-effectiveness of School BCG by % of cohort in high-risk group

‘High-risk’ as % of cohort10 year protection15 year protection
Additional cost (£K)QALYs gainedICER (£/QALY)Additional cost (£K)QALYs gainedICER (£/QALY)
0%£6515£123,557£58810£56,200
2%£6147£83,327£53514£38,312
4%£5789£60,983£48217£27,595
6%£54212£46,767£42921£20,458
8%£50614£36,926£37624£15,364
10%£46916£29,710£32328£11,544
12%£43318£24,192£27031£8,575
14%£39720£19,836£21735£6,200
16%£36122£16,309£16438£4,258
18%£32524£13,396£11142£2,639
20%£28826£10,950£5845£1,270

From: Appendix K, Health Economic Models

Cover of Tuberculosis
Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control.
NICE Clinical Guidelines, No. 117.
National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK).
Copyright © 2006, Royal College of Physicians of London.

For 2006 original guideline text, no part of the content may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other issue of this publication) without the written permission of the Royal College of Physicians of London. Applications for the Royal College of Physicians of London's written permission to reproduce any part of this publication should be addressed to the publisher.

For 2011 updated text, the material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.